Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Hoeper, N. Galie, L. Rubin, P. Jansa, A. Kusic-Pajic, G. Simonneau (Hannover, Germany; Bologna, Italy; La Jolla, United States Of America; Prague, Czech Republic; Allschwil, Switzerland; Clamart, France). Predictive factors of clinical worsening in functional class II patients with pulmonary arterial hypertension (PAH) in the EARLY trial of bosentan. Eur Respir J 2008; 32: Suppl. 52, 3179

Member's Comments

No comment yet.

Related content which might interest you: Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Prognostic risk factors of disease worsening in patients with functional class II pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Responses to sitaxsentan in patients with functional class II compared to III/IV pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registry Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Impact of the state of endothelium on clinical and functional parameters in COPD patients with arterial hypertension. Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017